New drug cocktail shows promise in rare stomach cancer trial

NCT ID NCT06109467

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respond to treatment. The approach targets cancers that overexpress HER2, a protein that helps cancer grow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Neratinib (a targeted cancer drug) combined with trastuzumab, pembrolizumab, and FOLFOX chemotherapy
What this could lead to
If successful, this could point toward a more effective treatment option for people with HER2-positive gastroesophageal cancers.
What could go wrong
This is a very small, early-phase trial with only 8 participants, so results may not apply to everyone. The drug combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.